Stiripentol is not a cost-effective treatment for Canadian Dravet syndrome patients, and decision-makers should consider funding it, according…
Ashraf Malhas, PhD
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.